CB-103 With Either Lenvatinib or Abemaciclib in Patients With NOTCH ACC
CB-103 With Either Lenvatinib or Abemaciclib in Patients With NOTCH ACC
Recruiting · NCT05774899 · Registry updated 2026-09-09Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| CB-103 With Either Lenvatinib or Abemaciclib in Patients With NOTCH ACC | Neoplasms by Histologic Type, adenocarcinoma, adenoid cystic carcinoma, carcinoma, epithelial neoplasm, neoplasm | Recruiting | Phase 1 / Phase 2 | 2026-09-09 | NCT05774899 |
3 results · Page 1 of 1
Organizations
Swipe the table sideways for more columns.
| Organizations | Linked trials |
|---|---|
| Adenoid Cystic Carcinoma Research Foundation | 3 |
| Cellestia Biotech AG | 1 |
| Michael J. Dennis, MD | 1 |
1 results · Page 1 of 1
Research sites
Swipe the table sideways for more columns.
| Research sites | City | Country | Linked trials |
|---|---|---|---|
| Dana Farber Cancer Institute | Boston | United States | 300 |